Non-fucosylated Anti-Human C5 (Olendalizumab) Therapeutic Antibody (CAT#: BioBet-087ZP) Datasheet

C5

Eculizumab; soliris; 219685-50-4; h5G1.1; DB01257 C5; complement component 5; complement C5; CPAMD4; anaphylatoxin C5a analog; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4; FLJ17816; FLJ17822; MGC142298;

Extracellular region or secreted

Diseases associated with C5 include Complement Component 5 Deficiency and Eculizumab, Poor Response To.

Its related pathways are Immune response Lectin induced complement pathway and Signaling by GPCR.

1.C5 activated by C5 convertase initiates the spontaneous assembly of late complement components C5-c9 to form a membrane attack complex. C5b has a short-term binding site for C6. The C5b-C6 complex is the basis for the assembly of the cleavage complex. 2.C5 anaphylactic shock toxin is derived from the proteolytic degradation of complement C5 and is the mediator of the local inflammatory process. Binding to the receptor C5AR1 can cause a variety of reactions, including intracellular calcium release, smooth muscle contraction, increased vascular permeability, and histamine release from mast cells and basophils (PubMed:8182049). C5a is also a powerful chemokine, which stimulates the movement of polymorphonuclear leukocytes and guides them to migrate to the site of inflammation.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG4, κ

Olendalizumab

Humanized

Human

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to C5. Olendalizumab is a humanized monoclonal antibody that can be potentially used in the treatment of Graft-versus-host disease, Antiphospholipid syndrome.

Neuromyelitis optica (NMO)

Neuromyelitis optica (NMO)